Inhibition of calpain-mediated cell death by a novel peptide inhibitor

Experimental Neurology

Volumn 202, Issue 2, 2006, Pages 506-513

  McCollum, Adrian T ^a   Jafarifar, Faegheh ^b   Lynn, Bert C ^b   Agu, Remigius U ^b,c   Stinchcomb, Audra L ^b   Wang, Susan ^b   Chen, Qinghua ^b   Guttmann, Rodney P ^b,d  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Calcium; Calpain; Cell death; Peptide; Phage display

Indexed keywords

CALPAIN; CALPASTATIN; LEUCYLSERYLGLUTAMYLALANYLLEUCINE; PROTEIN INHIBITOR; SPECTRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DEATH; CELL LINE; EMBRYO; FETUS; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMBRANE PERMEABILITY; NEUROBLASTOMA CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RAT; STROKE; TRAUMATIC BRAIN INJURY;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALPAIN; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUORESCEINS; IONOMYCIN; IONOPHORES; MASS SPECTROMETRY; NEURAL INHIBITION; NEURONS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SPECTRIN;

EID: 33750604951     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.07.016     Document Type: Article

References (41)

1. Bartus R.T., Baker K.L., Heiser A.D., Sawyer S.D., Dean R.L., Elliott P.J., and Straub J.A. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J. Cereb. Blood Flow Metab. 14 (1994) 537-544
2. Bartus R.T., Elliott P.J., Hayward N.J., Dean R.L., Harbeson S., Straub J.A., Li Z., and Powers J.C. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol. Res. 17 (1995) 249-258
3. Blomgren K. Calpastatin is upregulated and acts as a suicide substrate to calpains in neonatal rat hypoxia-ischemia. Ann. N. Y. Acad. Sci. 890 (1999) 270-271
4. Blomgren K., Kawashima S., Saido T.C., Karlsson J.O., Elmered A., and Hagberg H. Fodrin degradation and subcellular distribution of calpains after neonatal rat cerebral hypoxic-ischemia. Brain Res. 684 (1995) 143-149
5. Chemuturi N.V., Hayden P., Klausner M., and Donovan M.D. Comparison of human tracheal/bronchial epithelial cell culture and bovine nasal respiratory explants for nasal drug transport studies. J. Pharm. Sci. 94 (2005) 1976-1985
6. DeRidder M.N., Simon M.J., Siman R., Auberson Y.P., Raghupathi R., and Meaney D.F. Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol. Dis. 22 (2006) 165-176
7. Dutt P., Arthur J.S., Croall D.E., and Elce J.S. m-Calpain subunits remain associated in the presence of calcium. FEBS. Lett. 436 (1998) 367-371
8. Goll D.E., Thompson V.F., Li H., Wei W., and Cong J. The calpain system. Physiol. Rev. 83 (2003) 731-801
9. Guttmann R.P., and Johnson G.V. Oxidative stress inhibits calpain activity in situ. J. Biol. Chem. 273 (1998) 13331-13338
10. Guttmann R.P., Elce J.S., Bell P.D., Isbell J.C., and Johnson G.V. Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J. Biol. Chem. 272 (1997) 2005-2012
11. Guttmann R.P., Sokol S., Baker D.L., Simpkins K.L., Dong Y., and Lynch D.R. Proteolysis of the N-methyl-d-aspartate receptor by calpain in situ. J. Pharmacol. Exp. Ther. 302 (2002) 1023-1030
12. Guttmann R.P., Baker D.L., Seifert K.M., Cohen A.S., Coulter D.A., and Lynch D.R. Specific proteolysis of the NR2 subunit at multiple sites by calpain. J. Neurochem. 78 (2001) 1083-1093
13. Guttmann R.P., Day III G.A., Wang X., and Bottiggi K.A. Identification of a novel calpain inhibitor using phage display. Biochem. Biophys. Res. Commun. 333 (2005) 1087-1092
14. Hong S.C., Goto Y., Lanzino G., Soleau S., Kassell N.F., and Lee K.S. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 25 (1994) 663-669
15. Huang Y., and Wang K.K. The calpain family and human disease. Trends Mol. Med. 7 (2001) 355-362
16. Ma H., Yang H.Q., Takano E., Hatanaka M., and Maki M. Amino-terminal conserved region in proteinase inhibitor domain of calpastatin potentiates its calpain inhibitory activity by interacting with calmodulin-like domain of the proteinase. J. Biol. Chem. 269 (1994) 24430-24436
17. Maki M., Takano E., Mori H., Sato A., Murachi T., and Hatanaka M. All four internally repetitive domains of pig calpastatin possess inhibitory activities against calpains I and II. FEBS Lett. 223 (1987) 174-180
18. Marcum J.L., Mathenia J.K., Chan R., and Guttmann R.P. Oxidation of thiol-proteases in the hippocampus of Alzheimer's disease. Biochem. Biophys Res. Commun. 334 (2005) 342-348
19. Markgraf C.G., Velayo N.L., Johnson M.P., McCarty D.R., Medhi S., Koehl J.R., Chmielewski P.A., and Linnik M.D. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 29 (1998) 152-158
20. McCollum A.T., Nasr P., and Estus S. Calpain activates caspase-3 during UV-induced neuronal death but only calpain is necessary for death. J. Neurochem. 82 (2002) 1208-1220
21. McCollum A.T., Estus S., and Nasr P. NGF acts via p75 low-affinity neurotrophin receptor and calpain inhibition to reduce UV neurotoxicity. J. Neurosci. Res. 77 (2004) 552-564
22. McCollum A.T., Jafarifar F., Chan R., and Guttmann R.P. Oxidative stress inhibits ionomycin-mediated cell death in cortical neurons. J. Neurosci. Res. 76 (2004) 104-109
23. Melloni E., and Pontremoli S. The calpains. Trends Neurosci. 12 (1989) 438-444
24. Michetti M., Salamino F., Melloni E., and Pontremoli S. Reversible inactivation of calpain isoforms by nitric oxide. Biochem. Biophys. Res. Commun. 207 (1995) 1009-1014
25. Minger S.L., Geddes J.W., Holtz M.L., Craddock S.D., Whiteheart S.W., Siman R.G., and Pettigrew L.C. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia. Brain Res. 810 (1998) 181-199
26. Mishizen-Eberz A.J., Guttmann R.P., Giasson B.I., Day III G.A., Hodara R., Ischiropoulos H., Lee V.M., Trojanowski J.Q., and Lynch D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86 (2003) 836-847
27. Moldoveanu T., Hosfield C.M., Lim D., Elce J.S., Jia Z., and Davies P.L. A Ca(2+) switch aligns the active site of calpain. Cell 108 (2002) 649-660
28. Murachi T., Tanaka K., Hatanaka M., and Murakami T. Intracellular Ca2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv. Enzyme Regul. 19 (1980) 407-424
29. Neumar R.W., Meng F.H., Mills A.M., Xu Y.A., Zhang C., Welsh F.A., and Siman R. Calpain activity in the rat brain after transient forebrain ischemia. Exp. Neurol. 170 (2001) 27-35
30. Ohba H., and Bakalova R. Relationships between degree of binding, cytotoxicity and cytoagglutinating activity of plant-derived agglutinins in normal lymphocytes and cultured leukemic cell lines. Cancer Chemother. Pharmacol. 51 (2003) 451-458
31. Rackoff J., Yang Q., and DePetrillo P.B. Inhibition of rat PC12 cell calpain activity by glutathione, oxidized glutathione and nitric oxide. Neurosci. Lett. 311 (2001) 129-132
32. Rami A., and Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 609 (1993) 67-70
33. Robinson A. Inhibiting calpain, rescuing cells. CMAJ 154 (1996) 193-195
34. Sun A., and Cheng J. Novel targets for therapeutic intervention against ischemic brain injury. Clin. Neuropharmacol. 22 (1999) 164-171
35. Tompa P., Mucsi Z., Orosz G., and Friedrich P. Calpastatin subdomains A and C are activators of calpain. J. Biol. Chem. 277 (2002) 9022-9026
36. Vanderklish P.W., and Bahr B.A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 81 (2000) 323-339
37. Wang K.K. Developing selective inhibitors of calpain. Trends Pharmacol. Sci. 11 (1990) 139-142
38. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci. 23 (2000) 20-26
39. Wang K.K., and Yuen P.W. Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol. 37 (1997) 117-152
40. Yadavalli R., Guttmann R.P., Seward T., Centers A.P., Williamson R.A., and Telling G.C. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J. Biol. Chem. 279 (2004) 21948-21956
41. Zalewska T. Calpain as proposed target for neuroprotective treatment of brain ischemia. Folia Neuropathol. 34 (1996) 121-127